JP2011513307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513307A5 JP2011513307A5 JP2010548745A JP2010548745A JP2011513307A5 JP 2011513307 A5 JP2011513307 A5 JP 2011513307A5 JP 2010548745 A JP2010548745 A JP 2010548745A JP 2010548745 A JP2010548745 A JP 2010548745A JP 2011513307 A5 JP2011513307 A5 JP 2011513307A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- pharmaceutical composition
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 21
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 229910052805 deuterium Inorganic materials 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000020832 chronic kidney disease Diseases 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 206010022562 Intermittent claudication Diseases 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 4
- 208000017667 Chronic Disease Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 200000000007 Arterial disease Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 206010019663 Hepatic failure Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims description 2
- 201000001431 Hyperuricemia Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010067362 Radiation necrosis Diseases 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 208000026723 Urinary tract disease Diseases 0.000 claims description 2
- 208000012931 Urologic disease Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 208000012998 acute renal failure Diseases 0.000 claims description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims description 2
- 231100000268 induced nephrotoxicity Toxicity 0.000 claims description 2
- 230000000155 isotopic effect Effects 0.000 claims description 2
- 208000007903 liver failure Diseases 0.000 claims description 2
- 231100000835 liver failure Toxicity 0.000 claims description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 230000000414 obstructive effect Effects 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 208000014001 urinary system disease Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 201000005665 thrombophilia Diseases 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 2
- 229960001476 pentoxifylline Drugs 0.000 description 2
- 0 *C(*)(*)C(*)(*)C(*)(*)C(*)(*)C(*)(*)N(C(c1c(N2*)nc(*)[n]1*)=O)C2=O Chemical compound *C(*)(*)C(*)(*)C(*)(*)C(*)(*)C(*)(*)N(C(c1c(N2*)nc(*)[n]1*)=O)C2=O 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6773608P | 2008-02-29 | 2008-02-29 | |
| US61/067,736 | 2008-02-29 | ||
| US13456808P | 2008-07-11 | 2008-07-11 | |
| US61/134,568 | 2008-07-11 | ||
| US19871508P | 2008-11-07 | 2008-11-07 | |
| US61/198,715 | 2008-11-07 | ||
| PCT/US2009/001294 WO2009108375A1 (en) | 2008-02-29 | 2009-02-27 | Substituted xanthine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011513307A JP2011513307A (ja) | 2011-04-28 |
| JP2011513307A5 true JP2011513307A5 (enExample) | 2013-04-25 |
| JP5292413B2 JP5292413B2 (ja) | 2013-09-18 |
Family
ID=40600003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010548745A Active JP5292413B2 (ja) | 2008-02-29 | 2009-02-27 | 置換キサンチン誘導体 |
| JP2010548747A Expired - Fee Related JP5567503B2 (ja) | 2008-02-29 | 2009-02-27 | 置換キサンチン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010548747A Expired - Fee Related JP5567503B2 (ja) | 2008-02-29 | 2009-02-27 | 置換キサンチン誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20090239886A1 (enExample) |
| EP (3) | EP2265612B1 (enExample) |
| JP (2) | JP5292413B2 (enExample) |
| KR (1) | KR20100121527A (enExample) |
| CN (1) | CN101998957B (enExample) |
| AU (1) | AU2009217680B2 (enExample) |
| BR (1) | BRPI0908107A2 (enExample) |
| CA (1) | CA2716788C (enExample) |
| EA (1) | EA019088B1 (enExample) |
| MX (1) | MX2010009300A (enExample) |
| WO (2) | WO2009108383A2 (enExample) |
| ZA (1) | ZA201006104B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100121527A (ko) | 2008-02-29 | 2010-11-17 | 콘서트 파마슈티컬즈, 인크. | 치환된 잔틴 유도체 |
| KR101671537B1 (ko) | 2008-08-11 | 2016-11-01 | 넥타르 테라퓨틱스 | 다분지형 중합체 알카노에이트 컨쥬게이트 |
| US20100087455A1 (en) * | 2008-10-06 | 2010-04-08 | Auspex Pharmaceuticals, Inc. | Substituted xanthine compounds |
| WO2010075086A2 (en) * | 2008-12-15 | 2010-07-01 | Auspex Pharmaceuticals, Inc. | Pyrrolidinone inhibitors of pde-4 |
| US20110053961A1 (en) * | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
| CA2771331A1 (en) | 2009-09-02 | 2011-03-10 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| WO2011028820A1 (en) | 2009-09-02 | 2011-03-10 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
| WO2012031072A1 (en) | 2010-09-01 | 2012-03-08 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
| WO2012031068A1 (en) * | 2010-09-01 | 2012-03-08 | Concert Pharmaceuticals, Inc. | Method of utilizing recycled deuterium oxide in the synthesis of deuterated compounds |
| US9074233B2 (en) | 2010-09-01 | 2015-07-07 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
| EP2611807A2 (en) * | 2010-09-01 | 2013-07-10 | Concert Pharmaceuticals Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)dione |
| US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| WO2012166459A1 (en) * | 2011-05-27 | 2012-12-06 | Bristol-Myers Squibb Company | Tripeptides incorporating deuterium as inhibitors of hepatitis c virus |
| US20140296263A1 (en) * | 2011-07-19 | 2014-10-02 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| CN104364255A (zh) | 2012-04-13 | 2015-02-18 | 康塞特医药品有限公司 | 取代的黄嘌呤衍生物 |
| US20150087660A1 (en) * | 2012-05-10 | 2015-03-26 | Mahesh Kandula | Compositions and methods for the treatment of chronic diseases and inflammatory disorders |
| MX2016010213A (es) | 2014-02-07 | 2017-04-13 | Auspex Pharmaceuticals Inc | Formulaciones farmaceuticas novedosas. |
| WO2015160913A1 (en) | 2014-04-18 | 2015-10-22 | Concert Pharmaceuticals, Inc. | Methods of treating hyperglycemia |
| WO2015175008A1 (en) * | 2014-05-14 | 2015-11-19 | Concert Pharmaceuticals, Inc. | Methods of treating chronic kidney disease characterized by macroalbuminuria |
| US10954300B2 (en) | 2015-09-28 | 2021-03-23 | The Trustees Of Columbia University In The City Of New York | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma |
| CN108348525B (zh) * | 2015-10-29 | 2021-09-10 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物的医药用途 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2330742C2 (de) | 1973-06-16 | 1982-07-29 | Hoechst Ag, 6000 Frankfurt | 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| JPS5576876A (en) | 1978-12-05 | 1980-06-10 | Grelan Pharmaceut Co Ltd | Preparation of 1-(oxoalkyl)-3,7-dimethylxanthine derivatne |
| JPS55122779A (en) | 1979-03-13 | 1980-09-20 | Maruko Seiyaku Kk | Preparation of theobromine derivative |
| CS201558B1 (en) | 1979-05-14 | 1980-11-28 | Pavol Kovar | Method of preparing 1-/5-oxohexyl/-3,7-dimethylxanthine |
| JPS567785A (en) | 1979-07-02 | 1981-01-27 | Maruko Seiyaku Kk | Preparation of theobromine derivative |
| JPS5610187A (en) | 1979-07-05 | 1981-02-02 | Grelan Pharmaceut Co Ltd | Separation and purification of 1-(5-oxohexyl)- 3,7-dimethylxanthine |
| JPS5610188A (en) | 1979-07-06 | 1981-02-02 | Dainippon Ink & Chem Inc | Xanthine derivative and its preparation |
| JPS5632477A (en) | 1979-08-27 | 1981-04-01 | Nippon Iyakuhin Kaihatsu Kenkyusho:Kk | Preparation of 1- 5-oxohexyl -3,7-dimethylxanthine |
| JPS5677279A (en) | 1979-11-28 | 1981-06-25 | Ota Seiyaku Kk | Preparation of xanthine derivative |
| JPS5711981A (en) | 1980-06-26 | 1982-01-21 | Sagami Chem Res Center | Theobromine derivative and its preparation |
| JPS5724386A (en) | 1980-07-17 | 1982-02-08 | Nissan Chem Ind Ltd | Preparation of xanthine derivative |
| JPS5724382A (en) | 1980-07-17 | 1982-02-08 | Nissan Chem Ind Ltd | Trithiane derivative and its preparation |
| JPS5724385A (en) | 1980-07-17 | 1982-02-08 | Nissan Chem Ind Ltd | Theobromine derivative and its preparation |
| JPS5756481A (en) | 1980-09-22 | 1982-04-05 | Kawashima Yakuhin Kaihatsu Kk | Production of 1-(5-oxohexyl)-3,7-dimethylxanthine |
| JPS5762278A (en) | 1980-10-01 | 1982-04-15 | Sagami Chem Res Center | Theobromine derivative and its preparation |
| JPS5780385A (en) | 1980-11-05 | 1982-05-19 | Mitsubishi Petrochem Co Ltd | Preparation of 1-((omega-1)-oxoalkyl)-3,7-dialkylxanthine |
| JPS5785387A (en) | 1980-11-14 | 1982-05-28 | Teikoku Chem Ind Corp Ltd | Preparation of 1-(-5'-oxohexyl)-3,7-dimethylxanthine |
| JPS5798284A (en) | 1980-12-10 | 1982-06-18 | Kawashima Yakuhin Kaihatsu Kk | Preparation of 1-(5-oxohexyl)-3,7-dimethylxanthine |
| JPS57200391A (en) | 1981-06-02 | 1982-12-08 | Daito Koeki Kk | 1-(5-oxo-2-hexenyl)3,7-dimethylxanthine |
| JPS5838284A (ja) | 1981-09-01 | 1983-03-05 | Teikoku Chem Ind Corp Ltd | １−（５′−オキソヘキシル）−３，７−ジメチルキサンチンの製造方法 |
| JPS58134092A (ja) | 1982-02-05 | 1983-08-10 | Sagami Chem Res Center | テオブロミン誘導体 |
| JPS58150594A (ja) | 1982-03-03 | 1983-09-07 | Daito Koeki Kk | キサンチン誘導体の製造方法 |
| CS237719B1 (cs) | 1983-05-12 | 1985-10-16 | Jan Jendrichovsky | SpAsob přípravy dimetyl-(5-oxohexyl)-xantlnov |
| DE3508097A1 (de) | 1984-07-21 | 1986-02-06 | Hoechst Ag, 6230 Frankfurt | Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung |
| DE3525801A1 (de) * | 1985-07-19 | 1987-01-22 | Hoechst Ag | Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung |
| DD274334A3 (de) | 1985-12-17 | 1989-12-20 | Dresden Arzneimittel | Verfahren zur herstellung von reinem 3,7-dimethyl-1-(5-oxohexyl)-xanthin |
| IL106861A (en) | 1986-12-31 | 1997-02-18 | Hoechst Roussel Pharma | Pentoxifylline metabolites and pharmaceutical formulations containing them for inhibiting the activity of interleukin-1 and leukocyte-derived cytokines |
| CS263595B1 (sk) | 1988-01-06 | 1989-04-14 | Rybar Alfonz | Spdsob pripravy 7-n-prnpyl-3-metyl 3,7-dihydro-lH-purín-2,6-dionu |
| JP2661666B2 (ja) | 1988-02-19 | 1997-10-08 | ヘキスト薬品工業株式会社 | 抗消化性潰瘍剤 |
| IT1231779B (it) | 1989-08-09 | 1991-12-21 | Eniricerche Spa | Procedimento per l'ossidazione di composti paraffinici. |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| DE3942872A1 (de) | 1989-12-23 | 1991-06-27 | Hoechst Ag | Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen |
| US5112827A (en) * | 1990-05-18 | 1992-05-12 | Board Of Regents, The University Of Texas System | Drug to reverse fatty liver and atheromatous lesions |
| AU9084991A (en) | 1990-11-01 | 1992-05-26 | Board Of Regents, The University Of Texas System | Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues |
| EP0484785B1 (en) | 1990-11-07 | 1996-05-22 | Hoechst-Roussel Pharmaceuticals Incorporated | Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses |
| IL100195A0 (en) | 1990-11-30 | 1992-08-18 | Hoechst Roussel Pharma | Use of xanthines for the preparation of a medicament having immuno suppressing activity |
| US6420374B1 (en) | 1990-11-30 | 2002-07-16 | Fred Hutchinson Cancer Research Center | Use of xanthines as immunosuppressants and to inhibit allograft reactions |
| IL100194A0 (en) * | 1990-11-30 | 1992-08-18 | Hoechst Roussel Pharma | Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans |
| US5648357A (en) * | 1992-03-04 | 1997-07-15 | Cell Therapeutics, Inc. | Enatiomerically pure hydroxylated xanthine compounds |
| US5763446A (en) | 1992-03-26 | 1998-06-09 | University Of Southern California | Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases |
| US5780476A (en) * | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
| US5670506A (en) * | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
| US6020337A (en) * | 1993-04-05 | 2000-02-01 | Cell Therapeutics, Inc. | Electronegative-substituted long chain xanthine compounds |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| HUT68560A (en) | 1993-08-02 | 1995-04-27 | Chinoin Gyogyszer Es Vegyeszet | The use of xantine derivatives for promotion of healing of operative lesions |
| KR100477070B1 (ko) * | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| JPH10507156A (ja) | 1994-05-16 | 1998-07-14 | セル・セラピューティックス・インコーポレーテッド | キラル第二級アルコールの不斉合成 |
| DE4430128A1 (de) | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
| DE4430127A1 (de) * | 1994-08-25 | 1996-03-14 | Hoechst Ag | Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat |
| AU3539795A (en) | 1994-08-25 | 1996-03-14 | Medical University Of South Carolina | Methods of treating cold symptoms using pentoxifylline |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE19544768C1 (de) | 1995-11-30 | 1997-07-10 | Rentschler Arzneimittel | Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose |
| US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| US5985592A (en) | 1997-06-05 | 1999-11-16 | Dalhousie University | Uses for pentoxifylline or functional derivatives/metabolites thereof |
| US6248889B1 (en) | 1998-11-20 | 2001-06-19 | 3M Innovative Properties Company | Process for converting an alcohol to the corresponding fluoride |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| US6417208B1 (en) | 1999-02-05 | 2002-07-09 | Albert Einstein College Of Medicine Of Yeshiva University | Method of identification of inhibitors of PDE1C |
| US6316458B1 (en) * | 1999-04-30 | 2001-11-13 | Cell Therapeutics, Inc. | Method of enhancing insulin action |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| GB0102107D0 (en) | 2001-01-26 | 2001-03-14 | Syngenta Ltd | Chemical process |
| CZ20033211A3 (cs) | 2001-05-03 | 2004-09-15 | F. Hoffmann-La Roche Ag | Farmaceutická léková forma amorfního nelfinavir mesylátu |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Pharmaceuticals, Inc. | Delivery of drug esters through an inhalation route |
| WO2003013568A1 (en) | 2001-08-02 | 2003-02-20 | Ortho-Mcneil Pharmaceutical, Inc. | Cytokine modulation therapy |
| KR20040053210A (ko) | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
| AU2003220342B2 (en) | 2002-03-14 | 2007-06-07 | Bayer Pharmaceuticals Corporation | Methods of treating diabetes using PDE 11A inhibitors |
| DE10214228A1 (de) | 2002-03-22 | 2003-10-02 | Bdd Group Holding Ag Zug | Deuterierte substitutierte Indole sowie diese Verbindungen enthaltende Arzneimittel |
| US20050107420A1 (en) * | 2002-05-23 | 2005-05-19 | Boehringe Ingelheim Pharma Gmbh & Co. Kg | Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases |
| US7407955B2 (en) * | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| MXPA05013553A (es) | 2003-06-30 | 2006-03-09 | Altana Pharma Ag | Pirrolodihidroisoquinolinas como inhibidores de pde10. |
| EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
| WO2005023193A2 (en) | 2003-09-04 | 2005-03-17 | Interleukin Genetics, Inc. | Methods of treating endometriosis |
| BRPI0511854A (pt) | 2004-06-07 | 2008-01-15 | Pfizer Prod Inc | inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica |
| US20070292523A1 (en) | 2004-09-27 | 2007-12-20 | Joey Moodley | Dihydropyrimidine Formulations |
| WO2006039237A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| WO2008030382A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| KR20100121527A (ko) | 2008-02-29 | 2010-11-17 | 콘서트 파마슈티컬즈, 인크. | 치환된 잔틴 유도체 |
| US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
| US20110053961A1 (en) | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| US8485557B2 (en) | 2009-08-27 | 2013-07-16 | Kermit Zarley Enterprises | Self-supporting book |
| CA2771331A1 (en) * | 2009-09-02 | 2011-03-10 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
-
2009
- 2009-02-27 KR KR1020107021407A patent/KR20100121527A/ko not_active Abandoned
- 2009-02-27 MX MX2010009300A patent/MX2010009300A/es active IP Right Grant
- 2009-02-27 JP JP2010548745A patent/JP5292413B2/ja active Active
- 2009-02-27 WO PCT/US2009/001305 patent/WO2009108383A2/en not_active Ceased
- 2009-02-27 JP JP2010548747A patent/JP5567503B2/ja not_active Expired - Fee Related
- 2009-02-27 CA CA2716788A patent/CA2716788C/en active Active
- 2009-02-27 EP EP09715566.7A patent/EP2265612B1/en active Active
- 2009-02-27 AU AU2009217680A patent/AU2009217680B2/en active Active
- 2009-02-27 CN CN2009801114859A patent/CN101998957B/zh active Active
- 2009-02-27 EA EA201001391A patent/EA019088B1/ru not_active IP Right Cessation
- 2009-02-27 US US12/380,579 patent/US20090239886A1/en not_active Abandoned
- 2009-02-27 BR BRPI0908107A patent/BRPI0908107A2/pt not_active IP Right Cessation
- 2009-02-27 WO PCT/US2009/001294 patent/WO2009108375A1/en not_active Ceased
- 2009-02-27 EP EP17160882.1A patent/EP3199203B1/en active Active
- 2009-02-27 EP EP09714926A patent/EP2265334A2/en not_active Withdrawn
-
2010
- 2010-08-26 ZA ZA2010/06104A patent/ZA201006104B/en unknown
-
2013
- 2013-07-24 US US13/949,888 patent/US9035050B2/en active Active
-
2015
- 2015-05-15 US US14/713,423 patent/US9493463B2/en active Active